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INTRODUCTION
Plastic and reconstructive surgery has a well-recognized 
history of disruption and innovation.1–6 Our specialty has 
been defined by those who push the needle, such as Harry 
Buncke, an innovator in microsurgery, Joseph Murray, the 
Nobel Prize-winning pioneer of kidney transplantation, 
and Paul Tessier, a visionary for modern craniofacial sur-
gery.7–9 These narratives have permeated to successive gen-
erations of plastic surgeons, and echo the foundational 
principles of creativity and vision within our specialty. 
Plastic surgeons do not “own” a single organ in the body, 
and as a result, have relied on their ability to innovate to 
confer a sense of identity within our broader surgical com-
munity.7 We have followed suit of our visionaries and have 
ventured into new frontiers of our field—such as gender-
affirming surgery, targeted muscle reinnervation, facial 
transplantation, and the like—to contribute to the spirit 
of innovation. This entails the translation of a new idea, 
process, or product designed to save energy and improve 
patient care. The inherent problem-solving nature of plas-
tic surgery promotes a mindset of curiosity and inquiry. 
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Background: Plastic and reconstructive surgery has a well-recognized history of 
disruption and innovation. It remains unclear, however, how the specialty’s prior-
ity on innovation materializes into commercialization or bench to bedside led by 
plastic surgeons.
Methods: Our analysis utilized Pitchbook (Seattle, Wash.), a market database of 
companies and investors, for ventures that have designed innovations related to 
plastic and reconstructive surgery. Companies were categorized into 5 focus areas: 
provider (outpatient surgical or hospital entity), aesthetics (cosmetics/inject-
ables), devices (instrumentation, lasers, implants), regenerative medicine (tissue 
engineering/wound healing), and software (digital solutions). Company websites, 
LinkedIn (Sunnyvale, Calif.) profiles, and Crunchbase (San Francisco, Calif.) were 
reviewed to determine the leadership roles of plastic surgeons.
Results: Plastic surgeons primarily serve as advisors, as opposed to founders or 
chief executive officers (CEOs). Our analysis additionally found that provider and 
software solutions had a greater degree of plastic surgeon-led leadership, whereas 
regenerative medicine and device innovation remains less frequented. There was 
a relatively balanced representation of academic and private plastic surgeons in 
entrepreneurial pursuits.
Conclusions: Plastic surgeons typically serve as board advisors, as opposed to found-
ers and CEOs. Reasons for disengagement from leadership roles may include sat-
isfaction with clinical work, time constraint, lack of business knowledge, financial 
constraint, and opportunity cost associated with starting a venture. To promote 
participation in innovation, future studies should explore tangible ways to engage 
in such opportunities. In doing so, plastic surgeons can own the “organ” of innova-
tion, and continue to contribute to the legacy and the advancement of the specialty. 
(Plast Reconstr Surg Glob Open 2021;9:e3557; doi: 10.1097/GOX.0000000000003557; 
Published online 28 April 2021.)
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Plastic surgeons may source inspiration from the clinic, 
operating room, research laboratory, from patients, col-
leagues, or the world outside the hospital. These discover-
ies often take shape in the form of research publications 
and conference presentations for the academic commu-
nity. However, others may channel this spirit of innovation 
of their basic and clinical research through translation 
through commercialization.
With the tremendous growth of the aesthetic surgery, 
tissue engineering, and regenerative medicine industries, 
plastic surgeons have unparalleled scientific and surgical 
expertise with the potential to revolutionize our field.10,11 
While some may file patents and pursue incorporation 
as an organizational entity, others may choose to partici-
pate through key opinion leader (KOL) or advisory board 
member roles. Regardless, it remains unclear how plastic 
surgery’s priority of innovation materializes into oppor-
tunities for commercialization and how plastic surgeons 
participate in such endeavors.
We hypothesize that plastic surgeons are well-repre-
sented in leadership roles within regenerative medicine 
and device solutions, as their operative and clinical exper-
tise offer valuable contributions within these sectors. We 
additionally posit that there will be a greater proportion of 
academic practice plastic surgeons, relative to their private 
practice counterparts who engage in entrepreneurial pur-
suits, given their access to university-based resources such 
as research laboratories, affiliated incubators, and adjunct 
business schools. This investigation sought to understand 
the role of plastic surgeons in ventures that pertain to the 
specialty of plastic surgery.
METHODS
A retrospective review of United States-based plas-
tic surgery companies was performed using Pitchbook 
(Seattle, Wash.), a public market database composed of 
companies and investors. Data were analyzed from invest-
ments posted in January 1, 2011 through December 31, 
2019.12 Each company’s focus area was determined based 
through Google search (Google LLC, Mountainview, 
Calif.). Five focus areas were identified: provider (outpa-
tient surgical or hospital entity), aesthetics (cosmetics/
injectables), devices (instrumentation, lasers, prosthetics, 
implants), regenerative medicine (tissue engineering or 
wound healing solutions), and software (digital solutions 
for patients or surgeons). In addition, company websites, 
LinkedIn (Sunnyvale, Calif.) profiles, Crunchbase (San 
Francisco, Calif.), and Pitchbook were reviewed to deter-
mine the educational background and expertise of the 
executive leadership team.12–14 Company websites that 
were not in English were omitted for this analysis. The spe-
cific roles (ie, founder(s), chief executive officer (CEO), 
chief medical officer (CMO), advisors, etc.) held by plastic 
surgeons and other medical providers were recorded for 
each company.
RESULTS
A total of 64 companies were included in the analysis. 
Nearly a fifth (19%) of companies had plastic surgeons 
as founders, and 9 (14%) had them as CEOs. Plastic sur-
geons more commonly served as board advisory members, 
as they were represented in 23% of companies. Of the 40 
plastic surgeons involved in various leadership positions, 
there were 9 (23%) CEOs, 12 (30%) founders, 15 (37.5%) 
advisors, and 4 (10%) CMOs (Fig. 1). There was a rela-
tively even divide between the representation from aca-
demic (36%) and private practice (39%) surgeons. Of the 
93 founders represented, 39 (42%) had MD or MD/PhD 
degrees, followed by 22 (24%) having exclusively PhD 
degrees, 16 (17%) with master’s (ie, MBA, MSE, MSc, etc), 
13 (14%) with bachelor’s, 2 (2%) with JD, and 1 (1%) with 
a high school diploma as the highest educational degree 
completed (Fig.  2A). Approximately one-fifth of physi-
cians were not plastic surgeons, and instead hailed from 
dermatology, orthopedic surgery, and general medicine. 
Of the 63 CEOs analyzed, 16 (25%) had MD, MD/PhD, 
or MD/MBA degrees, 16 (25%) had PhDs, 17 (27%) had 
some type of master’s degree, and 14 (22%) had a bach-
elor’s in this executive role (Fig. 2B).
In terms of focus area, there were 9 aesthetic compa-
nies, 13 device, 15 provider, 5 software, and 22 regenera-
tive medicine solutions, amounting to a total of 64 ventures 
analyzed. Plastic surgeons comprised a relatively larger 
proportion of founders in software (60%) and provider 
(33%) solutions, as opposed to regenerative medicine 
(11%) and device (15%) solutions (Fig. 3A). In contrast, 
plastic surgeons had a balanced representation across 
focus areas, with the exception of regenerative medicine 
and device solutions in CEO roles (Fig. 3B).
DISCUSSION
Our results reveal the under-representation of plastic 
surgeons in the leadership structures of start-up ventures 
related to their idea or specialty. This finding has many 
potential origins. All are related potentially to the oppor-
tunity cost of choosing to run a start-up and of incurring 
significant risk associated with foregoing reimbursement 
associated with one’s own academic or private practice 
and activities that might provide a greater chance of insti-
tutional advancement or promotion. Time constraint is an 
additional consideration, as plastic surgeons must balance 
responsibilities as full-time clinicians, principal investiga-
tors, and educators. Financial constraints could also serve 
as a barrier to starting a company, as student debt and 
personal obligations may preclude some from entrepre-
neurial endeavors. Moreover, instead of starting a com-
pany, plastic surgeons may elect to maintain relationships 
with industry companies through serving as consultants, 
organizing clinical studies, and receiving royalties for the 
use of various devices, biologics, and software.15–18 On the 
other hand, plastic surgeons may choose not to partici-
pate in the process of commercialization due to potential 
conflicts of interest and concerns of how they are viewed 
by the public, patients, and fellow colleagues.19–23 Finally, 
entrepreneurship in the form of start-ups may be per-
ceived as high risk and may require a certain level of 
industry contacts and relationships with investors that 
most plastic surgeons do not seek.
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If involved, we found plastic surgeons commonly 
occupy roles on the advisory board. Such positions can 
allow plastic surgeons to contribute their experiences 
within academia, draw inspiration from their work, and 
remain at the forefront of innovation amidst these con-
straints.24–26 This method of participation within commer-
cialization and healthcare ventures has been increasingly 
common among physicians in all specialties, in addition to 
plastic surgery.24–26
According to our findings, plastic surgeons are more 
likely to be founders or CEOs of companies that offer 
provider solutions, such as private practices and ambula-
tory surgical centers (ASCs). Plastic surgeons may prefer 
to pursue entrepreneurial opportunities that are closely 
interlinked with daily surgical practice, as their reputa-
tional and financial success are dependent on favorable 
surgical patient outcomes and clinical productivity. The 
predominance of plastic surgeons as leaders in provider 
solutions could also be attributed to the fact that the 
majority of residency graduates pursue careers in private 
practice. In fact, some studies have estimated that 67%–
90% of plastic surgeons choose this path, and thus often 
serve in executive leadership positions (ie founder, CEO) 
in such practices.27,28 Additionally, one could consider the 
burgeoning role of ASCs, which have been regarded as 
optimal sites for surgical intervention, cost reduction, 
patient satisfaction, privacy, productivity, and convenience 
to both plastic surgeons and patients.29 The Center for 
Medicare and Medicare Services has also incentivized the 
use of ASCs, providing greater reimbursement to surgeons 
who are operative in these settings, as opposed to hospi-
tal outpatient departments.30 In all, provider solutions are 
Fig. 1. Roles of plastic surgeons in plastic surgery companies.
Fig. 2. a, educational levels of founders for plastic surgery–related companies. B, educational levels of ceos for plastic surgery–related 
companies.
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an accessible method by which plastic surgeons excel as 
leaders, and concurrently provide a high quality of care 
to their patients.
Software solutions, which comprise remote monitor-
ing, virtual surgical planning, and telemedicine, were 
most commonly (60%) led by plastic surgeons in execu-
tive leadership roles. This could be attributed to a prom-
ise of greater financial returns associated with digital 
health ventures.31 However, these companies represented 
only 8% of those analyzed in our study, and may sug-
gest a lag of digital health applications in plastic surgery. 
Interestingly, however, investment value in software and 
digital health has increased by 858% and the number of 
investments by 412%, in the past decade.31 Institutional 
efforts have been taken to increase investment in digital 
health, specifically the Food and Drug Administration 
(FDA)’s establishment of the Digital Health Center of 
Excellence. This entity aims to empower stakeholders to 
advance healthcare through response and high-quality 
innovation.32 Within the field of plastic surgery, there are 
great opportunities for digital health ventures. Virtual sur-
gical planning and simulation technologies are attractive 
from the standpoint of offering precision care for optimal 
aesthetic results for patients. Telemedicine, defined as the 
use of information technology and telecommunication to 
provide healthcare, has great potential for use within plas-
tic surgery—whether through triaging trauma patients, 
monitoring postoperative wounds, or performing consul-
tations for elective procedures.33 With the resurgence of 
the Coronavirus pandemic, digital heath solutions within 
all specialties, including plastic surgery, will continue to 
rise in the coming months.34 Given the promise of digital 
health innovation, we urge plastic surgeons to leverage 
their surgical expertise and consider the applications of 
software solutions for the sake of improving clinical out-
comes and aesthetic results for patients.
Regenerative medicine solutions, composed of tissue 
engineering and wound healing companies, had a low 
representation (11%) of plastic surgeons as founders and 
CEOs. Instead, engineers and research scientists, with 
PhDs, comprised the vast majority of leaders in such com-
panies. Furthermore, the FDA and national government 
has increasingly prioritized innovation within regenerative 
medicine, allocating greater research and development 
funds through the 21st Century Cures Act.35 From a finan-
cial perspective, the tissue engineering market is quite 
robust, as the market amounted to $9.0 billion in 2019, 
and is expected to rise at a compound annual growth rate 
of 14.2% from 2020 to 2027.4 Although plastic surgeons 
have variable interests in the applications of basic science 
to their specialty, it is important to consider how academic 
plastic surgeons interact regularly within the fields of tis-
sue engineering, 3-dimensional printing, and biologics in 
the laboratory and thus, have great potential in translat-
ing their research discoveries to venture opportunities. 
Surgeons have unparalleled insight into the issues affect-
ing their patients, and can serve as a foundation of new 
ideas and insights, as well as revision of older constructs.
Device companies, which manufacture lasers, surgi-
cal instruments, implants, and prosthetics, also had a low 
representation (15%) of plastic surgeons in executive 
leadership roles. Through advisory roles, plastic surgeons 
Fig. 3. a, percentage breakdown of plastic surgeons as founders by company focus. B, percentage breakdown of plastic surgeons as ceos 
by company focus.
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may contribute their perspective as chief users of various 
devices; they may provide feedback regarding product 
features, settings, and utilization to company represen-
tatives. They carry comprehensive knowledge of a given 
device’s capabilities and limitations in a particular patient 
or medical condition. This clinical and practical expertise 
is unparalleled, and should serve as inspiration for plastic 
surgeons to start ventures that design and deliver devices, 
and ultimately, enhance care for patients.
There was a slightly greater representation of academic 
plastic surgeons, compared with those in private prac-
tice, within executive leadership positions. Such engage-
ment of academic plastic surgeons could be attributed 
to their increased access to surgical innovation incuba-
tors, interdisciplinary expertise, and technology transfer 
offices.36,37 Some academic institutions, such as University 
of Michigan (Surgical Innovation and Entrepreneurship 
Development Program), Stanford University (BioDesign), 
University of Utah, University of Minnesota (Innovation 
Fellows Program), Mayo Clinic (Center for Innovation), 
and Northwestern University (NUvention), have 
embraced an innovation agenda, spearheading a variety of 
entrepreneurship development programs and internship 
opportunities for surgical trainees.38–48 These programs 
may educate aspiring surgeon-entrepreneurs on topics 
such as product design, patent filing, licensing, talent 
recruitment, shareholder equity, and fundraising to drive 
clinical and research-borne innovations forward. These 
opportunities may integrate the expertise of adjunct busi-
ness, law, engineering, and design schools to build a well-
versed, diverse team. We advocate for a continued effort 
by academic plastic surgery sections and departments to 
share these offerings with trainees and faculty and ulti-
mately, encourage the utilization of these resources.38–48 
More broadly, we recommend that national plastic sur-
gery societies, such as the American Society of Plastic 
Surgeons and the Plastic Surgery Foundation, similarly 
encourage this agenda through offering seed grants and 
pitch opportunities to spur innovation amongst private 
and academic plastic surgeons. In addition, such societ-
ies may develop co-membership opportunities with other 
entities, such as business schools and other medical societ-
ies (ie, dermatology, otolaryngology) to foster synergy and 
commercialization.
To further explain their relative under-representa-
tion of leadership roles, plastic surgeons may abstain 
from engaging in entrepreneurial pursuits due to lack 
of business-related knowledge. Moreover, a recent study 
surveyed plastic surgery program directors and discovered 
discrepancies between perceived importance of a business 
education and the resources available for plastic surgery 
residents to learn about such concepts.49 Another study 
reported that nearly 90% of plastic surgeon respondents 
stated that business principles are either “pretty impor-
tant” or “very important” to being a doctor.50–52 Efforts 
to incorporate a business curriculum for plastic surgery 
residents have been undertaken at several institutions, 
such as Johns Hopkins University, Washington University 
School of Medicine, and our own, Yale University.53 These 
curricula have been administered through lecture series 
and case discussions, and have educated on topics such 
as billing and coding, leadership, investing, and negotia-
tion. Despite these advances, the adoption of a standard-
ized national curriculum within integrated plastic surgery 
residencies is yet to occur. We urge such institutions to 
leverage adjunct business, engineering, and law schools 
to share instruction on the process of commercialization, 
which may discuss the concrete steps that translate an idea 
to clinical reality. Future studies should assess whether 
such a curriculum translates to a greater probability of 
starting ventures within plastic surgery.
There are several limitations to this study that warrant 
consideration. First, our analysis does not have a record 
of all nonpublic funding investments, and thus does not 
account for all companies for which plastic surgeons 
may participate in. Such data are not available through 
Pitchbook. Second, the subjective characterization of 
investments may have introduced uncertainties, and thus, 
mislabeling of plastic surgeon engagement in various sec-
tors. Third, while company websites, LinkedIn profiles, 
and Crunchbase portals were assessed for involvement by 
plastic surgeons, these might not have comprehensively 
recorded their roles. This ultimately underestimates the 
engagement of plastic surgeons in executive leadership 
positions and informal advisory roles. Future studies could 
survey national plastic surgery societies to attain more 
granular information regarding participation and inter-
est in commercialization and entrepreneurship. Fourth, 
our study did not delve into the respective roles of aca-
demic and private plastic surgeons in a given commercial 
endeavor. Future investigations could elucidate how a par-
ticular clinical setting may be associated with innovation 
and formalized leadership in a given therapeutic area.
CONCLUSIONS
Despite these limitations, it is important to recognize 
the immense potential for plastic surgeons to engage in 
the process of commercialization. As a specialty known by 
its drive to innovate, we urge plastic surgeons to consider 
the application of their clinical and research-borne discov-
eries to impact patients beyond their scope of practice. 
Bench to bedside progression of ideas can be a driving 
force for innovation within the field of Plastic Surgery. 
Provider and software solutions had a greater degree of 
plastic surgeon-led leadership, and may reflect the ten-
dency to interlink one’s daily surgical practice with entre-
preneurship. Despite their emphasis on scientific and 
surgical experience, regenerative medicine- and device-
based ventures had less involvement by plastic surgeons in 
leadership positions. To promote participation within sur-
gical innovation, future studies should explore tangible 
ways in which plastic surgery residents, fellows, and attend-
ings can learn about business fundamentals, connect with 
a multi-disciplinary team, and leverage resources, such as 
patent attorneys, technology transfer offices, and grants, 
to be successful in their entrepreneurial pursuits. In doing 
so, plastic surgeons can comprehensively own the space of 
innovation, and contribute to the legacy of entrepreneur-
ship so passionately instilled in all of us—for the sake of 
patients and the advancement of the specialty.
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